Genentech Deal Looking Better; Avastin Misses in First Adjuvant Trial
Though some analysts believed Genentech Inc. could have gotten more than $95 per share for its remaining minority stake in the $46.8 billion deal with Roche Holdings AG earlier this year, the buyout price was looking pretty good Wednesday, after Genentech reported that cancer drug Avastin [...]